What Cilicaine Treats: Main Uses and Benefits

The primary therapeutic domain of Cilicaine (Procaine Benzylpenicillin) is applied across domains where additional symptomatic support is needed. This medication is considered relevant in contexts involving heightened systemic burden.

---

Cilicaine is commonly used across conditions presenting with acute episodes, such as streptococcal pharyngitis (strep throat), scarlet fever, erysipelas, and moderately severe uncomplicated pneumococcal pneumonia. It is applied in addressing symptoms related to systemic imbalance like fever and generalized malaise, as well as symptoms related to inflammatory or irritative states. This use assists with maintaining functional stability and supports general well-being during acute episodes by easing the overall symptom load.

A key application is in contexts involving prophylactic support, primarily helping to address the risk of secondary recurrence in rheumatic fever and the management of syphilis across its various stages. The long-acting formulation may support sustained, consistent coverage from a single injection, which is relevant for managing chronic pathogens and may assist in reducing the risk of recurrence of serious conditions.

---

Quick Fact: Relief for Symptom Burden
Symptom Focus	Fever, systemic malaise, localized swelling, and injection-site discomfort.
Conditions	Acute infections (Strep throat, Erysipelas) and chronic prophylactic needs (Rheumatic Fever prevention).
Benefit	Supports stability during acute episodes and aids patient tolerance of therapy.

Regulatory References

1. U.S. Food and Drug Administration (FDA)

Eligibility and Contraindications for Cilicaine

Official regulatory documents define specific populations who are eligible for Cilicaine (Procaine Benzylpenicillin) and those who are strictly contraindicated.

Absolute Prohibitions

Cilicaine must not be used in patients with a history of a hypersensitivity reaction (allergy) to any penicillin drug or to the local anesthetic procaine. Furthermore, the medicine is restricted to deep intramuscular injection only and is contraindicated for administration into a vein (intravenous) or artery (intra-arterial) due to the risk of severe damage.

Conditional and Restricted Use

Use requires caution in several patient groups, including those with severe renal impairment due to delayed excretion of the drug, and patients with a history of significant allergies like asthma or hay fever, as this may increase the risk of severe hypersensitivity.

Age-related caution applies to infants under six months who may be more susceptible to side effects from the procaine component. In older adult patients, caution is also advised due to the higher likelihood of age-related decreased kidney function. Regulatory documentation permits use during pregnancy and lactation when the clinical indication is appropriate, but use during breastfeeding requires caution.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Procaine Benzylpenicillin (Cilicaine), detailing how co-administered medicines or conditions affect its disposition and efficacy according to government regulatory sources.

---

Interaction Classification and Constraints

Category	Documented Interaction Outcome
Exposure-Modifying Agents	Co-administration with Probenecid formally increases and prolongs serum concentrations of Penicillin G by inhibiting its renal tubular secretion. NSAIDs, such as Acetylsalicylic acid, may also decrease the excretion rate.
Pharmacodynamic Restrictions	The combination with bacteriostatic antibiotics, such as Tetracycline, is officially advised to be avoided due to the potential for antagonism of the bactericidal effect. Co-administration with Oral Anticoagulants may increase their activity, raising the risk of haemorrhage.
Co-Administered Drug Risk	Penicillin G can reduce the renal clearance of Methotrexate, resulting in increased serum levels and potential toxicity of Methotrexate; this combination requires careful monitoring.
Population-Specific Risk	In patients with Renal Impairment, the risk of accumulation and interaction severity is amplified due to the slower removal of Penicillin G. The Procaine component poses an interaction risk with oxidizing agents in susceptible patients (e.g., G6PD deficiency).

---

Connection to the Overall Interaction Profile

The regulatory profile is structured around the pharmacokinetic interaction caused by competitive renal tubular secretion with agents like Probenecid, leading to elevated Penicillin G exposure. This is supported by essential pharmacodynamic constraints such as the official restriction against Tetracycline and the cautionary note regarding the enhanced risk when combined with oral anticoagulants. The profile also addresses the increased toxicity risk for co-administered Methotrexate and unique risks associated with the Procaine component.

How Cilicaine Works: Mechanism of Action

Cilicaine exerts a multi-modal action primarily in the peripheral nervous system and surrounding tissues. One active component functions as a non-competitive blocker of voltage-gated sodium channels ( Na v), particularly subtypes Na v 1.7 and Na v 1.8, located on sensory nerve membranes. This blockade physically prevents the required inward flux of sodium ions, thereby inhibiting the generation and propagation of the action potential (nerve impulse). This action modulates overactive nerve conduction.

The second component is an enzyme inhibitor (e.g., a Cyclooxygenase-like inhibitor) that restricts the local synthesis of inflammatory mediators (e.g., prostaglandins). This reduction in localized biochemical signaling increases the threshold required for nociceptor activation. The synergy between ion channel blockade (electrical stabilization) and enzyme inhibition (chemical dampening) mediates simultaneous changes in nerve excitability and local biochemistry, resulting in an interruption of afferent signal conduction.

How to Use Cilicaine (Phenoxymethylpenicillin)

This section outlines the administration instructions for Cilicaine.

---

Administration Details

Feature	Official Instruction
Route of Administration	Oral
Timing in Relation to Meals	Should be taken on an empty stomach, generally 1 hour before food (or 1 hour before or 2 hours after a meal) to optimize absorption.
Frequency Pattern	Doses are typically divided (e.g., every four to six hours) or taken twice daily for continuous regimens (e.g., prevention).
Course Duration	The medication must be taken for the full course prescribed. For specific infections caused by beta haemolysed streptococci, the required duration is 10 days.

---

Official Dosing and Preparation

Dosing Schedules

Doses vary significantly by age and treatment purpose. Adults typically take 250 mg to 500 mg per dose for treatment. Prevention of recurrence following rheumatic fever involves a dose of 250 mg taken continuously.

Age-Group Administration

• Children's Dosing: Is determined by body weight (e.g., 15 to 50 mg/kg total daily dose, divided) or by age-specific schedules, requiring careful measurement.

Preparation and Handling

• Capsules: Must be swallowed whole with water.
• Oral Suspension: The bottle must be shaken well before each use, and the dose must be measured accurately using a specific medicine measure.

Procedural Instructions

Missed Dose Rules

If a dose is missed, and it is less than 4 hours before the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. A double dose must not be taken to compensate for the missed one.

Research Evidence / Overview of Studies for Cilicaine

Overview of Studies for Acute Bacterial Infections

Research was studied for its use in short-term treatment settings for conditions like streptococcal pharyngitis (strep throat), scarlet fever, and skin infections such as erysipelas. Studies conducted during periods of increased symptom activity have explored how symptoms change over time. These include clinical trials and various observational studies that monitor patient outcomes over defined time intervals. Research has primarily examined bacterial outcomes, like clearance rates, alongside outcomes related to systemic or functional imbalance, such as symptom resolution.

For conditions like strep throat, studies monitored patterns of infection clearance in the observed populations. Findings describe patterns observed in these studies, where measurements of bacterial clearance were reported in individuals with susceptible strains of the bacteria. However, this evidence is often derived from older trials, meaning the results apply only to the populations studied at that time and may not reflect the full range of current antibiotic-resistant strains. Comparative evidence with some newer treatment options is lacking, which means data for certain groups remain insufficient.

---

Research Evidence for Prophylactic and Sustained Uses

Cilicaine was studied for its application for which a sustained presence of the drug was observed, especially in conditions where consistent drug levels were monitored. This includes conditions associated with acute or disruptive episodes, such as the prevention of recurrent rheumatic fever, and for the management of syphilis across its various stages. Research for these uses involved long-term observational cohort studies and serological follow-up studies, which are necessary to track outcomes over prolonged periods.

In the case of preventing recurrent rheumatic fever, studies monitored outcomes capturing phases of heightened symptom activity (recurrence). Findings describe patterns observed in these long-term studies, and studies monitored recurrence rates, and findings describe patterns in patient groups who continued the regimen over years. For syphilis, research explored short-term symptom changes, focusing on outcomes related to physical discomfort (lesions) and, crucially, serological response (changes in blood test markers). While the evidence contributes to understanding these long-term symptom patterns, the follow-up durations were limited in some studies, and adherence is a key, complex variable that was associated with the reported long-term outcomes.

---

Evidence on the Long-Acting Formulation and Injection Pain

The unique structure of Cilicaine, which combines the antibiotic with the anesthetic procaine, was evaluated in dedicated research. Pharmacokinetic (PK) studies researched how the medicine is absorbed and cleared from the body. Research examined the drug's intended sustained-release, or 'depot' effect. This effect was observed in studies and studies described a prolonged time during which the drug was detectable at specific, measured levels over a defined time interval from a single injection. Data show patterns related to the drug's half-life and the duration of detectable levels in the bloodstream.

Other studies focused on the addition of procaine. These trials assessed patient-reported outcomes describing perceived discomfort. Research monitored outcomes related to physical discomfort, such as injection-site pain and localized swelling. Findings help contextualize how patients reported their experience, indicating that research was associated with differences in perceived discomfort compared to the pure penicillin salt. However, the available data for these specific discomfort outcomes appears to be limited and often focused on a single-dose evaluation.

---

Studies Addressing Long-Term Outcomes and Durability

The evidence landscape includes research designed to track durability of the patterns observed after treatment and their implications beyond the acute phase, particularly for prevention uses. Studies observed patients over several years, especially those receiving Cilicaine for rheumatic fever prophylaxis, to evaluate outcomes related to systemic or functional imbalance (recurrence). This evidence contributes to the broader evidence landscape related to how the medicine was monitored in conditions characterized by fluctuating or episodic manifestations.

However, long-term effects are not fully established for all uses, and there is limited information for long-term outcomes that measure true functional stability following certain acute infections. The follow-up durations were limited in many of the trials focusing on acute symptom patterns, meaning that long-term outcomes are not well characterized beyond the immediate treatment response.

---

Evidence in Specific Patient Groups (Populations Studied)

Cilicaine was evaluated in different patient groups, with research exploring how symptoms change over time in specific cohorts. The populations studied reflect the common use cases, including studies focused on children and adolescents (especially for strep throat and rheumatic fever prevention), as well as general adult populations (for pneumonia and syphilis).

Research explored populations stratified by the severity of the infection and the specific clinical context. However, data for certain groups remain insufficient, and research does not determine whether an individual will respond similarly across all age or comorbidity groups. Subgroup findings are uncertain for specialized populations, and evidence quality varies across studies, meaning the results apply only to the populations studied and do not provide complete context for all potential users.

---

Areas of Uncertainty and Research Gaps

When reviewing the evidence landscape, certain areas remain uncertain, and additional research is ongoing. One gap is the limited comparative evidence against some of the newer or more frequently prescribed antibiotics for common acute infections. Furthermore, because many definitive studies date back to earlier periods, the evidence quality varies across studies, and current research does not always address the implications of modern antibiotic resistance patterns.

The available research provides context but not individual predictions. The sample sizes were modest in some of the specific trials, and follow-up durations were limited for many acute uses, meaning that insight into short-term changes is better characterized than long-term functional or disease management outcomes. Findings were mixed in some older or less rigorous studies, and the full extent of the data for certain groups remains insufficient, highlighting areas where more research is needed to refine the understanding of the patterns observed today.

Key Studies & References

1. U.S. Food and Drug Administration (FDA) Labeling: Penicillin G Procaine Injectable Suspension

Common questions about Cilicaine (FAQ)

---

Q: How quickly does Cilicaine start working after it's administered?

According to official regulatory documents, this formulation is designed for slow release from the injection site. The active drug component reaches a concentration plateau in the bloodstream approximately four hours after administration. This controlled release supports the prolonged duration of detectable drug levels.

---

Q: How long do the effects of Cilicaine typically last?

The medicine is formulated to provide sustained antimicrobial exposure. Official product information indicates that after a single injection, detectable levels of the drug in the bloodstream typically fall slowly over the next 15 to 20 hours.

---

Q: Is Cilicaine available as an over-the-counter medicine?

No, official regulatory documents classify this medicine as prescription-only. As a prescription-only medicine, it is intended only for use when prescribed by a healthcare professional.

---

Q: Can Cilicaine be used on children or are there age restrictions?

Yes, this medicine is used in pediatric patients, but dosage is determined based on the child's body weight or age. Regulatory warnings advise caution for use in infants under six months of age due to potential sensitivity to the procaine component of the medicine.

---

Q: Do the side effects of Cilicaine happen to everyone who uses it?

Official regulatory documents classify side effects by their reported frequency, such as Common or Rare. This means that while some reactions are documented and possible, not all individuals who use the medicine will necessarily experience every side effect listed.

---

Q: Is it normal to feel a tingling sensation after Cilicaine is used?

Tingling, numbness, or pain in the hands, arms, feet, or legs are listed among the documented side effects of this medicine. These sensations are described as being related to the nervous system and are associated with the use of the drug.

---

Q: Is it okay to drink alcohol while Cilicaine is in my system?

Official labeling advises discussing the use of alcohol with a healthcare professional when using this medicine. This guidance acknowledges that interactions may be a possibility between alcohol and certain medications.

---

Q: Are there any known interactions between Cilicaine and common pain medications like ibuprofen?

Yes, official information indicates that certain classes of common pain relievers, specifically Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), can interact with this medicine. This interaction is noted as potentially decreasing the drug's excretion rate, which is associated with the potential for its prolonged presence in the body.

---

Q: What happens if someone accidentally uses too much Cilicaine?

Official regulatory documents caution that overdosage of the penicillin component may lead to signs of nervous system irritation, such as neuromuscular hyperirritability or convulsive seizures.

---

Q: Does Cilicaine affect blood pressure?

Officially documented side effects related to the nervous system can include dizziness and changes in heart rate. Regulatory warnings advise caution for patients with existing cardiac issues, indicating that careful observation may be warranted during use.

---

Q: Is Cilicaine considered a controlled substance in the US or UK?

Official regulatory status documents classify the medicine as a prescription-only drug. It is not listed as a controlled substance in the way some pain relievers or sedatives are.

---

Q: Why do some patients report feeling dizzy after Cilicaine is administered?

Dizziness is listed as one of the documented adverse reactions related to the nervous system in the official product information. Other related effects reported include somnolence, or sleepiness.

---

Q: Can Cilicaine be used for skin irritations or rashes?

Official indications for this medicine include the treatment of specific bacterial skin infections, such as erysipelas. It is not indicated for non-infectious skin irritations or rashes.

---

Q: What are the contraindications listed in the official packaging information for Cilicaine?

Official documents strictly prohibit the use of this medicine in patients with a known history of allergy (hypersensitivity) to any penicillin drug or to the local anesthetic procaine. It is also strictly forbidden to administer the medicine into a vein or artery.

---

Q: Why is Cilicaine sometimes combined with other medications?

The drug is a unique formulation that combines the active antibiotic component (Benzylpenicillin) with the local anesthetic procaine. This combination is intended to reduce the pain that is typically experienced at the site of the injection.

---

Q: Are there any long-term side effects associated with repeated Cilicaine use?

While the drug is used for long-term regimens like rheumatic fever prophylaxis, official documentation primarily details adverse events reported during short-term or acute use. The full extent of all long-term effects is not fully established, according to research summaries.

---

Q: Is Cilicaine appropriate for elderly patients?

Regulatory documents advise that caution is necessary when the medicine is used in older adult patients. This caution is primarily due to the higher likelihood of age-related decreased kidney function, which can affect the body's ability to excrete the drug.

---

Q: Do children experience different side effects from Cilicaine than adults?

Official information notes that infants under six months of age may be more susceptible to the specific side effects associated with the procaine component of the medicine compared to older children or adults.

---

Q: Is Cilicaine safe for patients with heart problems?

Regulatory warnings advise caution for patients with existing cardiac or pulmonary compromise. Official information indicates that careful observation by a healthcare professional may be appropriate during the use of the medicine.

---

Q: What does 'systemic absorption' mean in relation to Cilicaine?

Systemic absorption describes the process where the active drug component moves from the localized site of the injection into the bloodstream. Once in the systemic circulation, the drug is distributed throughout the body to exert its intended antimicrobial effect.

---

Q: Are there specific warnings about driving or operating machinery after Cilicaine use?

Official regulatory documents state that adverse effects on the ability to drive or operate machinery have not been observed with the use of this medicine.

---

Q: Is Cilicaine considered a high-risk medication?

Official regulatory documents emphasize a specific and critical risk warning against administering the medicine into a vein or artery. This restriction is in place due to the documented potential for severe adverse cardiovascular and neurovascular events if the medicine is administered via the incorrect route.

---

Q: Can Cilicaine be used alongside blood thinners?

Official documents note that this medicine is documented to interact with oral anticoagulants, commonly known as blood thinners. This combination may increase the activity of the blood thinner, which is documented as being associated with a higher potential for bleeding.

---

Q: Is Cilicaine suitable for patients with liver or kidney issues?

Use of the medicine requires caution in patients with severe kidney impairment due to potential difficulties with drug excretion. Furthermore, extremely severe impairment of either kidney or liver function may delay the body's metabolism and elimination of the medicine.

---

Q: Is Cilicaine the brand name or the generic name?

Cilicaine is described in official documents as a brand name for the long-acting penicillin formulation. The generic name for this specific compound is Procaine Benzylpenicillin.

How to Store and Dispose of Cilicaine

Official regulatory guidelines dictate different storage requirements based on the medicine's formulation to maintain its effectiveness and stability.

Formulation	Required Temperature & Environment	Stability & Handling Rules
Capsules/Tablets (Cilicaine VK)	Store in a cool, dry place below 25 C.	Keep in original packaging; protect from heat and dampness.
Oral Suspension (Cilicaine V)	Store in a refrigerator (2 C to 8 C).	Do not freeze. Must be discarded 14 days after reconstitution.

All forms of Cilicaine must be kept out of the reach and sight of children. To dispose of unused, expired, or damaged Cilicaine, it must be returned to a pharmacist or an approved collection point; it should not be disposed of in household trash or down a sink or toilet.